WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the company's second-generation HIV maturation inhibitor, PA-1050040. Following review by the FDA, the Company intends to begin Phase 1 clinical trials of this new agent in the first quarter of 2007.
